<DOC>
	<DOC>NCT01001403</DOC>
	<brief_summary>This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.</brief_summary>
	<brief_title>Effect of Nafamostat on Postreperfusion Syndrome (PRS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nafamostat</mesh_term>
	<criteria>&gt;= 18 year old scheduled to undergo liver transplantation Previous history of pulmonary, cardiovascular, or renal disease Previous history of allergic reactions to nafamostat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>